摘要
目的比较帕利哌酮和阿立哌唑治疗精神分裂症患者的效果。方法选取2018年11月至2021年10月中国人民解放军联勤保障部队第九〇四医院收治的102例精神分裂症患者,采用随机数字表法将其分为帕利哌酮组(给予帕利哌酮治疗)和阿立哌唑组(给予阿立哌唑治疗),每组51例。连续治疗3个月后比较两组阳性与阴性症状量表(PANSS)评分、临床疗效、神经调节蛋白1(NRG1)及神经元特异性烯醇化酶(NSE)水平。比较两组治疗期间不良反应。结果PANSS评分组间比较、时间点比较及交互作用差异均有统计学意义(P<0.05)。进一步两两比较,组内比较:与治疗前比较,治疗1、3个后月两组PANSS评分均降低(P<0.05);与治疗1个月后比较,治疗3个后月两组PANSS评分均降低(P<0.05);组间比较:帕利哌酮组治疗1、3个月后PANSS评分均低于阿立哌唑组(P<0.05)。帕利哌酮组临床疗效优于阿立哌唑组(P<0.05)。治疗后两组NRG1水平与治疗前相比均升高,且帕利哌酮组NRG1水平高于阿立哌唑组(P<0.05);治疗后两组NSE水平则均降低,且帕利哌酮组NSE水平低于阿立哌唑组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论与阿立哌唑比较,帕利哌酮治疗精神分裂症可有效缓解临床症状,提高临床效果,调节血清神经调节蛋白水平,且安全可靠。
Objective To compare the efficacy of Paripipidone and Aripiprazole in the treatment of schizophrenia.Methods From November 2018 to October 2021,102 patients with schizophrenia admitted to the the 904th Hospital of the Joint Logistics Support Force of the Liberation Army were randomly divided into Paliperidone group(treated with Paliperidone)and Aripiprazole group(treated with Aripiprazole),with 51 cases in each group.Patients of the two groups were evaluated for the treatment effect after three months of continuous treatment.The positive and negative symptom scale(PANSS)scores,clinical efficacy,neuromodulin 1(NRG1),and neuron-specific enolase(NSE)levels were compared between the two groups.The adverse reactions during the treatment of the two groups were compared.Results There were significant differences in PANSS score betwee groups,time points,and interaction between groups(P<0.05).Further pairwise comparison,intra group comparison:compared with before treatment,the PANSS scores of the two groups decreased after one month and three months of treatment(P<0.05).Compared with one month after treatment,the PANSS scores of the two groups decreased after three months of treatment(P<0.05).Comparison between groups:the PANSS scores of Paliperidone group after one month and three months of treatment were lower than those of Aripiprazole group(P<0.05).The clinical effect of paripipidone group was better than Aripiprazole group(P<0.05).After treatment,the levels of NRG1 in the two groups were higher than those before treatment,and the level of NRG1 in the Paliperidone group was higher than that in the Aripiprazole group(P<0.05).After treatment,the NSE level of the two groups decreased,and the NSE level of the Paliperidone group was lower than that of the Aripiprazole group(P<0.05).There was no significant difference in the total incidence of adverse reactions between two groups(P>0.05).Conclusion Compared with Aripiprazole,Paliperidone in the treatment of schizophrenia can effectively relieve clinical symptoms,improve clinical efficacy,regulate serum neuregulin levels,and is safe and reliable.
作者
张瑞
杨春
ZHANG Rui;YANG Chun(Department of Military Psychiatric Medicine,the 904th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army,Jiangsu Province,Changzhou 213003,China;the 904th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army Youth,Jiangsu Province,Changzhou 213003,China)
出处
《中国医药导报》
CAS
2022年第22期153-156,共4页
China Medical Herald
基金
江苏省自然科学青年基金项目(BK20180213)。